OMCL
Omnicell Inc
$
31.430
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
31.470
Open
31.360
VWAP
31.34
Vol
125.39K
Mkt Cap
1.44B
Low
31.210
Amount
3.93M
EV/EBITDA(TTM)
12.95
Total Shares
45.92M
EV
1.36B
EV/OCF(TTM)
9.18
P/S(TTM)
1.28
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
294.76M
+4.37%
0.366
-34.6%
296.18M
-3.49%
0.494
-17.71%
278.67M
+3.34%
0.261
+0.55%
Estimates Revision
The market is revising Upward the revenue expectations for Omnicell, Inc. (OMCL) for FY2025, with the revenue forecasts being adjusted by 1.48% over the past three months. During the same period, the stock price has changed by 9.40%.
Revenue Estimates for FY2025
Revise Upward
+1.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+38.32%
In Past 3 Month
Stock Price
Go Up
+9.40%
In Past 3 Month
7 Analyst Rating
30.89% Upside
Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 41.14 USD with a low forecast of 32.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
30.89% Upside
Current: 31.430
Low
32.00
Averages
41.14
High
57.00
30.89% Upside
Current: 31.430
Low
32.00
Averages
41.14
High
57.00
Piper Sandler
Overweight
downgrade
$57 -> $55
2025-08-11
New
Reason
Piper Sandler
Price Target
$57 -> $55
2025-08-11
New
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Omnicell to $55 from $57 and keeps an Overweight rating on the shares. The firm notes the company raised 2025 guidance on Q2 strength across both segments and a dynamic China tariff situation. Piper updates its product gross margin forecast for the second half of 2025 and 2026 to reflect management's latest commentary and the expectation that mitigation efforts eliminate effectively all China tariff impact by Q4 2026.
Wells Fargo
Stan Berenshteyn
Overweight
maintain
$37 -> $40
2025-07-21
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$37 -> $40
2025-07-21
maintain
Overweight
Reason
Wells Fargo analyst Stan Berenshteyn raised the firm's price target on Omnicell to $40 from $37 and keeps an Overweight rating on the shares. The firm raises its 2025 adjusted EBITDA estimate above guided midpoint on a more favorable tariff setup post-90 day pause than we previously contemplated.
BofA
Neutral
downgrade
$34 -> $32
2025-07-14
Reason
BofA
Price Target
$34 -> $32
2025-07-14
downgrade
Neutral
Reason
BofA lowered the firm's price target on Omnicell to $32 from $34 and keeps a Neutral rating on the shares. BofA appreciates Omnicell's leading position in a duopolistic pharmacy automation market, but limited visibility into components of product revenue growth creates uncertainty near-term, the analyst tells investors in a research note.
Wells Fargo
Overweight
maintain
$35 -> $37
2025-05-23
Reason
Wells Fargo
Price Target
$35 -> $37
2025-05-23
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Omnicell to $37 from $35 and keeps an Overweight rating on the shares following the company's improved guidance outlook. While tariff risks remain fluid, the firm believes trade talks will likely steer outcomes toward the lower end of the risk range, supporting a more optimistic stance.
BofA
Allen Lutz
Neutral
maintain
$30 -> $34
2025-05-23
Reason
BofA
Allen Lutz
Price Target
$30 -> $34
2025-05-23
maintain
Neutral
Reason
BofA analyst Allen Lutz raised the firm's price target on Omnicell to $34 from $30 and keeps a Neutral rating on the shares after the company raised the low end of FY25 EPS and EBITDA guidance to reflect the latest announcement on China tariffs and also announced a $75M share repurchase program. The news is "a clear positive," but partly already reflected in shares, which have outperformed the S&P 500 index since May 9, the analyst tells investors.
Piper Sandler
NULL
to
Overweight
upgrade
$46 -> $57
2025-05-23
Reason
Piper Sandler
Price Target
$46 -> $57
2025-05-23
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Omnicell to $57 from $46 and keeps an Overweight rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Omnicell Inc (OMCL.O) is 20.40, compared to its 5-year average forward P/E of 32.00. For a more detailed relative valuation and DCF analysis to assess Omnicell Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
32.00
Current PE
20.40
Overvalued PE
43.30
Undervalued PE
20.70
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
20.04
Current EV/EBITDA
10.23
Overvalued EV/EBITDA
27.08
Undervalued EV/EBITDA
12.99
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
2.98
Current PS
1.21
Overvalued PS
4.58
Undervalued PS
1.38
Financials
Annual
Quarterly
FY2025Q2
YoY :
+4.98%
290.56M
Total Revenue
FY2025Q2
YoY :
+151.86%
8.12M
Operating Profit
FY2025Q2
YoY :
+50.98%
5.64M
Net Income after Tax
FY2025Q2
YoY :
+50.00%
0.12
EPS - Diluted
FY2025Q2
YoY :
-40.57%
26.83M
Free Cash Flow
FY2025Q2
YoY :
+6.37%
43.94
Gross Profit Margin - %
FY2025Q2
YoY :
-44.69%
7.76
FCF Margin - %
FY2025Q2
YoY :
+43.70%
1.94
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
567.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
349.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
567.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
349.9K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
OMCL News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
06:53:38
Omnicell lowers 2025 non-GAAP EPS view to $1.40-$1.65 from $1.65-$1.85
2025-07-31
06:51:24
Omnicell sees Q3 non-GAAP EPS 30c-37c, consensus 37c
2025-07-31
06:50:34
Omnicell reports Q2 non-GAAP EPS 45c, consensus 27c
Sign Up For More Events
Sign Up For More Events
News
4.0
08-11BenzingaPiper Sandler Maintains Overweight on Omnicell, Lowers Price Target to $55
4.0
07-12NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 7/12/2025
4.0
06-18NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 6/18/2025
Sign Up For More News
People Also Watch
COCO
Vita Coco Company Inc
33.220
USD
-0.06%
HLMN
Hillman Solutions Corp
10.105
USD
-2.37%
TGS
Transportadora de Gas del Sur SA
27.615
USD
-3.65%
LION
Lionsgate Studios Corp
6.565
USD
+0.84%
BEAM
Beam Therapeutics Inc
17.560
USD
+0.23%
VITL
Vital Farms Inc
48.080
USD
+0.71%
CTRI
Centuri Holdings Inc
20.400
USD
-1.02%
TALO
Talos Energy Inc
8.105
USD
-2.47%
FL
Foot Locker Inc
25.590
USD
-1.58%
DBRG
DigitalBridge Group Inc
11.185
USD
-2.65%
FAQ
What is Omnicell Inc (OMCL) stock price today?
The current price of OMCL is 31.43 USD — it has increased 0.29 % in the last trading day.
What is Omnicell Inc (OMCL)'s business?
What is the price predicton of OMCL Stock?
What is Omnicell Inc (OMCL)'s revenue for the last quarter?
What is Omnicell Inc (OMCL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Omnicell Inc (OMCL)'s fundamentals?
How many employees does Omnicell Inc (OMCL). have?